| pubmed-article:18182807 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18182807 | lifeskim:mentions | umls-concept:C0022671 | lld:lifeskim |
| pubmed-article:18182807 | lifeskim:mentions | umls-concept:C0026473 | lld:lifeskim |
| pubmed-article:18182807 | lifeskim:mentions | umls-concept:C0242606 | lld:lifeskim |
| pubmed-article:18182807 | lifeskim:mentions | umls-concept:C0023981 | lld:lifeskim |
| pubmed-article:18182807 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:18182807 | pubmed:dateCreated | 2008-1-9 | lld:pubmed |
| pubmed-article:18182807 | pubmed:abstractText | Uremia has been implicated in increased oxidative stress (OS) and decreased monocyte HLA-DR expression in chronic kidney disease (CKD) patients. Thus, one would expect normalization of these parameters after successful kidney transplant (KTx). Our aim was to describe patterns of OS and HLA-DR expression after KTx and to explore the effect of renal function and different immunosuppression regimens. 30 KTx patients (20 male; 48 +/- 11 years) were enrolled and compared with 20 healthy controls. We measured advanced oxidation protein products (AOPP) and the percentage of monocytes expressing HLA-DR (%DR+) before (preKTx) and after KTx (on days 2, 30, 90, 180 and after 1 year). Compared to controls, patients had a higher preKTx AOPP (152.6 vs. 69.3 micromol/l; p < 0.001). AOPP decreased at 48 h after KTx, achieving values similar to controls. Thereafter, it increased again and remained significantly higher compared to controls, returning to preKTx levels at 90 days. Prior to KTx there was a trend for lower %DR+ in KTx patients compared to controls (96 vs. 98%; NS). Following KTx, patients had a lower %DR+ in the 1st month; then it gradually returned to preKTx levels during the 1st year; at no time did it reach a value similar to controls. Cyclosporine (CyA)-treated patients had a significantly higher AOPP (161.5 vs. 99.5 micromol/l; p = 0.03) and a lower %DR+ (91.7 vs. 96.4; p < 0.05) at 30 days than patients on tacrolimus (FK). Patients on mycophenolate mofetil (MMF) showed a low AOPP (106.9 vs. 168.1 micromol/l; p = 0.05) and a high %DR+ (96.7 vs. 88.2%; p = 0.001) than those on everolimus. After 3 months, CyA-treated patients had a non-significant increase in AOPP levels, whereas those on FK showed a decrease (p < 0.05) as did those treated with MMF (p < 0.05). Successful KTx reduced but did not normalize AOPP, suggesting ongoing OS, perhaps due to persistent mild renal dysfunction and the effects of immunosuppression. HLA-DR expression remained low after KTx, which may be a possible contributing factor to infectious complications after transplantation. Immunosuppressive agents appear to have diverse effects on OS and HLA-DR expression. | lld:pubmed |
| pubmed-article:18182807 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18182807 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18182807 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18182807 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18182807 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18182807 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18182807 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18182807 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18182807 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18182807 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18182807 | pubmed:issn | 1421-9735 | lld:pubmed |
| pubmed-article:18182807 | pubmed:author | pubmed-author:RoncoClaudioC | lld:pubmed |
| pubmed-article:18182807 | pubmed:author | pubmed-author:SilvaSandraS | lld:pubmed |
| pubmed-article:18182807 | pubmed:author | pubmed-author:ChiaramonteSt... | lld:pubmed |
| pubmed-article:18182807 | pubmed:author | pubmed-author:DissegnaDanie... | lld:pubmed |
| pubmed-article:18182807 | pubmed:author | pubmed-author:NalessoFederi... | lld:pubmed |
| pubmed-article:18182807 | pubmed:author | pubmed-author:de... | lld:pubmed |
| pubmed-article:18182807 | pubmed:author | pubmed-author:CruzDinnaD | lld:pubmed |
| pubmed-article:18182807 | pubmed:author | pubmed-author:CorradiValent... | lld:pubmed |
| pubmed-article:18182807 | pubmed:author | pubmed-author:LentiniPaoloP | lld:pubmed |
| pubmed-article:18182807 | pubmed:author | pubmed-author:BassoFlavioF | lld:pubmed |
| pubmed-article:18182807 | pubmed:author | pubmed-author:GoepelVolkerV | lld:pubmed |
| pubmed-article:18182807 | pubmed:copyrightInfo | (c) 2008 S. Karger AG, Basel. | lld:pubmed |
| pubmed-article:18182807 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:18182807 | pubmed:volume | 26 | lld:pubmed |
| pubmed-article:18182807 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18182807 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18182807 | pubmed:pagination | 105-10 | lld:pubmed |
| pubmed-article:18182807 | pubmed:dateRevised | 2010-11-18 | lld:pubmed |
| pubmed-article:18182807 | pubmed:meshHeading | pubmed-meshheading:18182807... | lld:pubmed |
| pubmed-article:18182807 | pubmed:meshHeading | pubmed-meshheading:18182807... | lld:pubmed |
| pubmed-article:18182807 | pubmed:meshHeading | pubmed-meshheading:18182807... | lld:pubmed |
| pubmed-article:18182807 | pubmed:meshHeading | pubmed-meshheading:18182807... | lld:pubmed |
| pubmed-article:18182807 | pubmed:meshHeading | pubmed-meshheading:18182807... | lld:pubmed |
| pubmed-article:18182807 | pubmed:meshHeading | pubmed-meshheading:18182807... | lld:pubmed |
| pubmed-article:18182807 | pubmed:meshHeading | pubmed-meshheading:18182807... | lld:pubmed |
| pubmed-article:18182807 | pubmed:meshHeading | pubmed-meshheading:18182807... | lld:pubmed |
| pubmed-article:18182807 | pubmed:meshHeading | pubmed-meshheading:18182807... | lld:pubmed |
| pubmed-article:18182807 | pubmed:meshHeading | pubmed-meshheading:18182807... | lld:pubmed |
| pubmed-article:18182807 | pubmed:meshHeading | pubmed-meshheading:18182807... | lld:pubmed |
| pubmed-article:18182807 | pubmed:meshHeading | pubmed-meshheading:18182807... | lld:pubmed |
| pubmed-article:18182807 | pubmed:meshHeading | pubmed-meshheading:18182807... | lld:pubmed |
| pubmed-article:18182807 | pubmed:meshHeading | pubmed-meshheading:18182807... | lld:pubmed |
| pubmed-article:18182807 | pubmed:meshHeading | pubmed-meshheading:18182807... | lld:pubmed |
| pubmed-article:18182807 | pubmed:meshHeading | pubmed-meshheading:18182807... | lld:pubmed |
| pubmed-article:18182807 | pubmed:meshHeading | pubmed-meshheading:18182807... | lld:pubmed |
| pubmed-article:18182807 | pubmed:meshHeading | pubmed-meshheading:18182807... | lld:pubmed |
| pubmed-article:18182807 | pubmed:meshHeading | pubmed-meshheading:18182807... | lld:pubmed |
| pubmed-article:18182807 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18182807 | pubmed:articleTitle | Oxidative stress and 'monocyte reprogramming' after kidney transplant: a longitudinal study. | lld:pubmed |
| pubmed-article:18182807 | pubmed:affiliation | Department of Nephrology, Dialysis and Transplant, St. Bortolo Hospital, Vicenza, Italy. | lld:pubmed |
| pubmed-article:18182807 | pubmed:publicationType | Journal Article | lld:pubmed |
